Download TEACHERS - Pharmaceutical Economics and Policy

TEACHERS - Pharmaceutical Economics and Policy - PEP
Name: Sheila
Surname: Weir
Function: Head of Project Management
Email: [email protected]
Address: Basel
Nationality:
Teaching in PEP:
Cost of Research and Development of Pharmaceuticals
Education:
University Strathclyde B.Sc.UK. Biochemistry and Pharmacology.
University of Manchester, UK. Cardiovascular Pharmacology
Professional experience:
Sheila W. Weir is Newron Ph. Spa, Head, of Project Management since 2007. She received
her B.Sc. university education in Scotland and her doctorate in Cardiovascular
Pharmacology at the university of Manchester UK.
For over 20 years, Dr. Weir has worked in international research and drug development
departments of 2 major pharmaceutical companies, including Ciba-Geigy (Switzerland) and
Sandoz/Novartis (Switzerland/USA).
She started her career 1985 as a cardiovascular scientist at Ciba-Geigy. In 1988 at Sandoz
she held the position of clinical project manager in the dept of international clinical
development.
From 1990 to 1996; she was International Project Manager, Project Management at Sandoz
Pharma (Switzerland) overseeing development of products in CNS.
From 1996 to 1998, she served as the Head of Project Management, Genetic Therapy
Incorporated (USA) a Sandoz/Novartis company.
From late 1998 to mid 2004, she served as the Global Head of Project and Portfolio
Management at Novartis Consumer Health (Switzerland).
Between 2004 and 2007, Dr. Weir was the Head of Contract Manufacturing for Novartis
(Switzerland). In this later capacity she was responsible for the management of the global
third-party supplier network for Pharmaceutical Operations.
During her tenure in the pharmaceutical industry Dr. Weir has worked in and is very familiar
with all phases (pre-clinical through III) of drug development as well as in product
commercialization (phase IV) and out licensing. Overall, she has had responsibility for the
development of numerous products in several therapeutic and category areas. She has
been involved in numerous investigational new drug applications, and international new
OTC applications. In addition, she has also contributed to the scientific literature, including
13 papers and 15 abstracts, posters and presentations.
Fields of interest:
International Drug Development